本研究在体证实了MSA中存在胆碱能通路特异性损伤，尤其PPN-丘脑通路作为运动调控关键枢纽，其损伤程度与疾病严重度密切关联。该发现不仅深化了对MSA病理机制的理解，也为未来开发胆碱能通路靶向治疗策略提供了影像学依据。团队下一步将推进多中心纵向研究，验 ...

MSA作为一种进展性神经退行性疾病，其病理核心为α-突触核蛋白在少突胶质细胞中异常沉积形成的胶质胞质包涵体。既往尸检研究提示脑干脚桥核（PPN）和基底前脑Meynert核（NBM）的胆碱能神经元显著丢失，但对其投射通路的在体评估及临床关联仍缺乏系统研究。 团队纳入103例MSA患者与44名健康对照者，通过多模态磁共振数据重建三条关键胆碱能通路：NBM-内侧皮层通路（经扣带回）、NBM-外侧皮层通路 ...

Please provide your email address to receive an email when new articles are posted on . Multiple system atrophy — whose worldwide awareness day is commemorated every Oct. 3 — includes disorders that ...

The fundamental cause of multiple system atrophy (MSA) is a loss of oligodendroglial and neuronal cells in the brain and central nervous system. The loss of cells is gradual and progressive, leading ...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Multiple system atrophy (MSA) is a neurodegenerative disease that affects involuntary body functions such as blood pressure and heart rate as well as movement. It is similar to Parkinson's disease, ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Scientists have found a way to distinguish between two progressive neurodegenerative diseases, Parkinson's disease (PD) and multiple system atrophy (MSA). Scientists have found a way to distinguish ...

In the past, researchers believed that Parkinson's disease did not affect life expectancy. But recent studies showed a somewhat shorter life span. Now a new study suggests that when the disease does ...